PepBank has 5 Ovagen studies with results. 4 of them gave Ovagen, with 14 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 14 results and 9 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Ovagen is a synthetic 3-residue peptide in the Khavinson bioregulator family. Its sequence is Glu-Asp-Leu. Chemical identity does not establish a clinical benefit or a safe human dose. The peptide differs from the veterinary follicle-stimulating hormone product with the same name.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
3 amino acids
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 3.55 · Net charge at pH 7.4: −2.06
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 1.00 |
| 1 | 1.00 |
| 2 | 0.96 |
| 3 | 0.61 |
| 4 | −0.72 |
| 5 | −1.78 |
| 6 | −1.98 |
| 7 | −2.02 |
| 8 | −2.20 |
| 9 | −2.72 |
| 10 | −2.96 |
| 11 | −3.00 |
| 12 | −3.00 |
| 13 | −3.00 |
| 14 | −3.00 |
3 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 444128(opens in a new tab)
CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
5 of 9 studies have results (56%), published 2014 to 2018. Top row: every study. Bottom row: studies with results about Ovagen (EDL), by class. The rows use different scales.
Studies9 in all, 2011 to 2018
Studies with results5 in all, 2014 to 2018
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
9 studies match. Retracted studies are left out.
Showing 5 of 9 studiesquery qry_dd7399283b4cbbe33959e717
5 studies
Not a test of Ovagen (EDL) alone · 2016
Khavinson et al. 2016Bulletin of experimental biology and medicinecited by 9
PMID 27909961DOI 10.1007/s10517-016-3596-7PUB-27909961
In vitro (cells) · 2014
VKh et al. 2014Bulletin of experimental biology and medicinecited by 6
PMID 24958378DOI 10.1007/s10517-014-2540-yPUB-24958378
Animal study (in vivo) · rat · 2017
Zamorskii et al. 2017Bulletin of experimental biology and medicinecited by 4
PMID 28744634DOI 10.1007/s10517-017-3811-1PUB-28744634
Animal study (in vivo) · rat · 2018
Zamorskii et al. 2018Advances in gerontology = Uspekhi gerontologiicited by 1
PMID 30607912PUB-30607912
In vitro (cells) · 2014
VKh et al. 2014Advances in gerontology = Uspekhi gerontologii
PMID 25946838PUB-25946838
These studies name Ovagen (EDL) but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: none · 2011
Fedoreyeva et al. 2011Biochemistry. Biokhimiiacited by 29
PMID 22117547DOI 10.1134/s0006297911110022PUB-22117547
PubMed tag: none · 2013
Fedoreyeva et al. 2013Biochemistry. Biokhimiiacited by 8
PMID 23581987DOI 10.1134/s0006297913020053PUB-23581987
PubMed tag: none · 2017
Fedoreyeva et al. 2017Biochemistry. Biokhimiiacited by 8
PMID 28371610DOI 10.1134/s0006297917040149PUB-28371610
Indexing hint: Animal study · 2015
Zamorskii et al. 2015Bulletin of experimental biology and medicinecited by 7
PMID 26515176DOI 10.1007/s10517-015-3062-yPUB-26515176
Page 1 of 1
Zamorskii II · Bulletin of experimental biology and medicine · 2017
Animal study (in vivo) · rat · 7 results
Zamorskii II · Advances in gerontology = Uspekhi gerontologii · 2018
Animal study (in vivo) · rat · 18 results
Khavinson VKh · Bulletin of experimental biology and medicine · 2014
In vitro (cells) · 1 result
Khavinson VKh · Advances in gerontology = Uspekhi gerontologii · 2014
In vitro (cells) · 5 results
Khavinson VK · Bulletin of experimental biology and medicine · 2016
Not a test of Ovagen (EDL) alone · 2 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | Drugs@FDA returned NOT_FOUND for Ovagen, Glu-Asp-Leu and three PubChem Latin synonyms in brand and active-ingredient fields. This search did not establish approval absence under every possible name. Compounding status remains unresolved. | 22 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | No matching name occurred in 2,754 EMA central medicine records. The search checked Ovagen, Glu-Asp-Leu and glutamyl-aspartyl-leucine spellings. This search does not establish approval absence. EU national authorisations were not checked. | 22 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Status unknown The official 2026 list does not name Ovagen or Glu-Asp-Leu. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | Registered in Russia as a dietary supplement, not as a medicine. It is not approved as a medicine. Current supplement certificate RU.77.99.88.003.R.002087.08.25 of 2025-08-12 (earlier 77.99.23.3.U.9173.8.06), read from a copy of the supplement register (reestrinform.ru, accessed 2026-10-22). The manufacturer also lists it as a dietary supplement. No entry in the State Register of Medicines was found. | 22 Oct 2026 | reestrinform.ru (opens in a new tab) |
Reported effects from study results.
No safety results from studies in people
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Ovagen (EDL): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 4 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Kidney functionKidney and urinary | No results | Animal: 6 results from 2 studies: 1 increase, 4 decrease, 1 not reported. Strongest design: Animal study (in vivo) | No results | No results | 6 |
| Aging markersAging and longevity | No results | No results | Lab: 5 results from 1 study: 2 increase, 3 decrease. Strongest design: In vitro (cells) | No results | 5 |
| Oxidative stressKidney and urinary | No results | Animal: 2 results from 1 study: 1 increase, 1 decrease. Strongest design: Animal study (in vivo) | No results | No results | 2 |
| Receptor activity and mechanismKidney and urinary | No results | No results | Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells) | No results | 1 |
4 outcome groups shown of 4 · 14 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.